Back to search results

EUS-RFA PANCARDINAL-1 Trial for Pancreatic Cancer

This study is testing a new approach for pancreatic cancer (Pancreatic Ductal Adenocarcinoma or PDAC). It combines Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA), which uses heat to target cancer cells, with standard chemotherapy (Neoadjuvant Chemotherapy or NAC). The chemotherapy will be either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane). The goal is to see if this combination can shrink tumors or stop cancer spread before surgery, making surgery more effective. You may be eligible if you are 18 or older, have confirmed PDAC, and have not had extensive prior chemotherapy. The study aims to enroll 60 participants and is currently recruiting, though its exact status is unclear.

Study design
This is an interventional study, meaning participants will receive specific treatments. It plans to enroll 60 participants.
What's involved
You would receive Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) and Neoadjuvant Chemotherapy (NAC) before potential surgery.
Compensation
Not stated in the trial record.
Follow-up
The primary goal is measured from the time of EUS-RFA NAC intervention to the time of surgical tumor resection, which is about 5-6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04990609

EUS-RFA PANCARDINAL-1 Trial

Recruiting
PHASE2Ages 18+InterventionalTreatment
The University of Texas Health Science Center, Houston
~60 participants
Updated 2026-07-29 on ClinicalTrials.gov
What's tested:Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA)Neoadjuvant Chemotherapy (NAC)

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants who are able to complete neoadjuvant chemotherapy plus EUS-RFA and later undergo surgical tumor resection
Measured over From the time of EUS-RFA NAC intervention to the time of surgical tumor resection (about 5-6 months)

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Explore related trials

Pancreatic Ductal Adenocarcinoma

NCT04990609

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Memorial Hermann Hospital

    Houston, Texasstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Nirav Thosani, MD · PRINCIPAL_INVESTIGATOR · The University of Texas Health Science Center, Houston

Who to contact

Amatullah Alibhai, B.A., M.B.A.
[email protected]
713-486-1443
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosed and histologically-confirmed PDAC by biopsy
Permanent street address
Consent to study participation
Axial CT scan consistent with PDAC
No prior chemotherapy or less than 2 months of pre-operative chemotherapy for PDAC
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

Exclusion

Male or female patients \< 18 years of age
No permanent street address or telephone number
Pregnant patients
Inmates or prisoners
Unable to provide informed consent

What this trial measures

  • Number of participants who are able to complete neoadjuvant chemotherapy plus EUS-RFA and later undergo surgical tumor resectionFrom the time of EUS-RFA NAC intervention to the time of surgical tumor resection (about 5-6 months)